Inogen, Inc. (INGN)
Nasdaq · Healthcare · Medical Devices
$5.94−0.50%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $158M
- 52-week range
- $5.05 – $9.13
- 52-week change
- −30.50%
- EPS (trailing)
- −$0.92
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $349M (+3.86%)
- Net income
- $22.7M
- Operating margin
- −8.7%
- Diluted EPS
- −$0.86
- Free cash flow
- −$13.7M
From the company’s annual report on SEC EDGAR.
About Inogen, Inc.
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
Headquarters: Beverly, United States · 753 employees · provider.inogen.com